AP NEWS

Pancreatitis: Pipeline Review, H2 2018 - Featuring GlaxoSmithKline, Novartis, Takeda Pharma, Sun BioPharma, and more - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Pancreatitis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Pancreatitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 1, 15, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Featured News & Press Releases (2017-2018)

Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis CalciMedica Names Two Senior Executives to its Board of Directors Cypralis to present pre-clinical data on novel cyclophilin D inhibitor CC-1233 for acute pancreatitis at the American Pancreatic Association meeting Cypralis granted new Innovate UK feasibility stage award to develop cyclophilin inhibitors targeting fibrotic diseases Sun BioPharma Provides Clinical Update CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

Companies Featured

Angion Biomedica Corp Bharat Serums and Vaccines Ltd CalciMedica Inc Cypralis Ltd DiaMedica Therapeutics Inc Generon (Shanghai) Corp Ltd GlaxoSmithKline Plc LipimetiX Development Inc MallInckrodt Plc Novartis AG Pharming Group NV Shenzhen HighTide Biopharmaceutical Ltd Sun BioPharma Inc Takeda Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/njxhj9/pancreatitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005530/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs ,Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 12:01 PM/DISC: 09/17/2018 12:01 PM

http://www.businesswire.com/news/home/20180917005530/en

AP RADIO
Update hourly